Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 7/20 | 0.57 |
| ▸ | CTSL | P07711 | 6/20 | 0.57 |
| ▸ | CTSS | P25774 | 5/20 | 0.57 |
| ▸ | CTSK | P43235 | 4/20 | 0.52 |
| ▸ | ECE1 | P42892 | 1/20 | 0.47 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5963186 | 0.90 | CTSB (0.57) | CTSBCTSLCTSSCTSKDGAT1 | |
| SCHEMBL1849406 | 0.87 | CTSS (0.59) | CTSBCTSLCTSSCTSKECE1 | |
| SCHEMBL27964688 | 0.86 | CTSS (0.58) | CTSBCTSLCTSSCTSKECE1 | |
| SCHEMBL1852485 | 0.86 | CTSS (0.58) | CTSBCTSLCTSSCTSKECE1 | |
| SCHEMBL27753302 | 0.85 | ECE1 (0.62) | CTSBCTSLCTSSCTSKECE1 | |
| SCHEMBL1850128 | 0.85 | ECE1 (0.62) | CTSBCTSLCTSSCTSKECE1 | |
| SCHEMBL1844711 | 0.81 | CTSL (0.57) | CTSBCTSLCTSSCTSKECE1 | |
| SCHEMBL1701581 | 0.80 | CTSL (0.65) | CTSBCTSLCTSSCTSKPPARG | |
| SCHEMBL1796250 | 0.80 | CTSL (0.65) | CTSBCTSLCTSSCTSKPPARG | |
| SCHEMBL2487005 | 0.80 | CTSL (0.65) | CTSBCTSLCTSSCTSKPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1430045-B1 | PYRANE DERIVATIVES AS BOTH ACE- AND NEP-INHIBITORS | NOVARTIS AG (CH) | 2006-10-11 | — | — | EP | disclosed |
| US-20060194742-A1 | Pyrane derivatives as both ACE- and NEP-inhibitors | FINK CYNTHIA A | 2006-08-31 | — | — | US | disclosed |
| US-7071169-B2 | Pyrane derivatives as both ACE-and NEP-inhibitors | NOVARTIS AG (CH) | 2006-07-04 | — | — | US | disclosed |
| US-20040266698-A1 | Pyrane derivatives as both ace-and nep-inhibitors | FINK CYNTHIA ANNE (US) | 2004-12-30 | — | — | US | disclosed |
| EP-1430045-A1 | PYRANE DERIVATIVES AS BOTH ACE- AND NEP-INHIBITORS | Novartis AG (CH) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003027091-A1 | PYRANE DERIVATIVES AS BOTH ACE- AND NEP- INHIBITORS | NOVARTIS AG (CH) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194742-A1 | Pyrane derivatives as both ACE- and NEP-inhibitors | ECE1, ECE2, AGTR1 | CTSB 549/4885CTSL 545/4885CTSS 494/4885 |
| US-20040266698-A1 | Pyrane derivatives as both ace-and nep-inhibitors | ECE1, AGTR1, ACE | CTSB 790/4885CTSL 618/4885CTSS 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.